Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8(+) T cells compared with women with BRCA wild-type disease during the early disease course

Những quyển sách tương tự

• Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study
  Bằng: Lee, Jung-Min, et al.
  Được phát hành: (2018)
• Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
  Bằng: Lampert, Erika J, et al.
  Được phát hành: (2020)
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
  Bằng: O’Sullivan, Ciara C., et al.
  Được phát hành: (2014)
• A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer
  Bằng: Gatti‐Mays, Margaret E., et al.
  Được phát hành: (2020)
• Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
  Bằng: Lee, Jung-Min, et al.
  Được phát hành: (2015)